George, your numbers may be right on the money, but the main thing to users is what will their cost be after insurance. I suspect that will run the gamut between zero coverage and zero cost. Personally my Drs. are often surprised, first by the fact that they don't have to fight when prescribing certain drugs for me, and finally when I tell them with my coverage I'm getting the drug for free. Often they're drugs that have triple digit list prices. I don't believe the insurance pays triple digits, but I'll never know. I do have coverage from two insurance companies plus medicare, so my coverage is better than most, but my wife isn't covered by both companies and her copays aren't that different from mine.
Drug companies need to consider what happens after patent coverage ends. I believe the courts were wrong doing what they did with Vascepa, but AMRN has dealt with it by lowering their prices to the point that while I received the generics for awhile, now I'm getting the name brand. It may take them longer to be profitable, but I believe in time they will be.
Meanwhile, many people still pay substantial premiums for name brands, like Bayer Aspirin that sits right next to the Kirkland generic at Costco, though I really doubt there is much difference. Personally I've bought the Kirkland product for almost everything and often found it better than the name brand, which they often also sell for less than at other stores.
I doubt if our products will ever be available without prescription, at least not in the US, perhaps it will be elsewhere. I know people who go to Mexico to buy bulk amounts of drugs which would require a prescription here with no prescription required. The drugs appear to be made by the same companies, but made in Mexico. The people are satisfied that they're the same, I can't vouch for it. Of course the cost is dramatically lower.
With worldwide acceptance of our drug revenue won't be a concern no matter how low the pills are priced. Billions in earnings and growing each quarter will become common and that should warrant a P/E of 30 or more. Even if our O/S grows to a couple hundred million shares, well over double what it is today, our share price will be at or approaching triple digits.
Gary
Bullish
